Crude Oil (CL)

La cadena de opciones muestra datos clave de las opciones de acciones de Colgate-Palmolive a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Colgate-Palmolive..

Colgate-Palmolive (NYSE:CL) Bolsa, Cadena de Opciones

Colgate-Palmolive

Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.

Colgate-Palmolive Co

Core One Labs Inc

CHINA LIAONING DINGXU ECO by China Liaoning Dingxu Ecological Agriculture Development, Inc.

China Liaoning Dingxu Ecological Agriculture Development Inc

Clarus Corp

CHAVANT CAPITAL ACQUISITION CORP UNIT 1 COM & 1/3 WT EXP

CLARITAS PHARMACICLS INC by CLARITAS PHARMACEUTICALS INC.

Claritas Pharmaceuticals Inc

Core Laboratories Inc

CALBEE Inc

Columbia Financial Inc

CALIBER ENERGY INC by Caliber Energy, Inc.

Colombier Acquisition Corp. II Class A Ordinary Shares

Colombier Acquisition Corp II

Colombier Acquisition Corp. II Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant

Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share

Cellebrite DI Ltd

CHRISTINA LAKE CANNABIS by Christina Lake Cannabis Corp.

Christina Lake Cannabis Corp

CLICKS GROUP LTD S/ADR by Clicks Group Ltd

Clicks Group Ltd

CENTRAL CHINA SECS S/ADR by Central China Securities Co. Ltd.

Calcol Inc

Sinch AB

Cool Co Ltd

CEL Corp

Cell Source Inc

CapitaLand China Trust

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics Inc

Direxion Daily Cloud Computing Bull 2X Shares

Chatham Lodging Trust (REIT) Common Shares of Beneficial Interest

Chatham Lodging Trust

Chatham Lodging Trust (REIT) 6.625% Series A Cumulative Redeemable Preferred Shares of Beneficial Interest

Cloud3 Ventures Inc Ordinary Shares (Sub Voting)

CLOUD3 VENTURES INC by CLOUD3 VENTURES INC

Cloud3 Ventures Inc

Calidi Biotherapeutics Inc Warrants (01/01/9999)

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

Coles Group Ltd

COLES GROUP LTD UNSP/ADR by Coles Group Ltd.

China Liberal Education Holdings Limited - Ordinary Shares

China Liberal Education Holdings Ltd

CONCRETE LEVELING SYS INC by Concrete Leveling Systems Inc.

Concrete Leveling Systems Inc

Cleveland-Cliffs Inc

Clearfield Inc

CLIFFORD MDERN IVING HLD by CLIFFORD MODERN LIVING HLDGS LTD.

CLARITY METALS CORP by Clarity Metals Corp.

Clarity Metals Corp

Aris Mining Corp

CLEGHORN MINERALS ORD by Cleghorn Minerals

Cleghorn Minerals Ltd

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies Ltd

CLEANGO INNOVATIONS INC by CleanGo Innovations Inc.

CleanGo Innovations Inc

CLEAN SEED CAP GROUP LTD by Clean Seed Capital Group Ltd

Clean Seed Capital Group Ltd

Cloud Nine Web3 Technologies Inc

HUTECH21 CO LTD NEW by Hutech21 Co., Ltd.

Hutech21 Co Ltd

Clean Harbors Inc

ClearDAO

CLST Holdings Inc

COLTENE HOLDING AG ORD by Coltene Holding AG

Coltene Holding AG

Tidal Trust II Veridien Climate Action ETF

Energy Plug Technologies Corp

CORDLIFE GROUP LTD ORD by Cordlife Group Ltd

Cordlife Group Ltd

CLS HOLDINGS PLC ORD by CLS Holdings Plc.

CLS Holdings PLC

Click Holdings Ltd

CAPITALAND INVESTMENT LTD by Capitaland Investment Ltd.

CapitaLand Investment Ltd

CLEAN EARTH ACQUISITIONS CORP RT

CLEAN EARTH ACQUISITIONS CORP UNIT 1 CL A COM & 1 RT 1/2 RED WT EXP

CLEAN EARTH ACQUISITIONS CORP RED WT EXP

Global X Funds Global X 1-3 Month T-Bill ETF

ClearSign Technologies Corporation - Common Stock

ClearSign Technologies Corp

CLEARFORD WATER SYS INC by Clearford Water Systems, Inc.

Clearford Water Systems Inc

CLICKSTREAM CORP by ClickStream Corporation

ClickStream Corp

CITY OF LONDON INVST GRP by City of London Investment Group PLC

City of London Investment Group PLC

ProShares Long Online/Short Stores ETF

Clarke Inc

Calcitech Ltd

TWC ENTERPRISES LTD ORD by TWC Enterprises Ltd.

TWC Enterprises Ltd

CLAYTON & LAMBERT MFG CO by Clayton & Lambert Manufacturing Co.

CHALLENGER GOLD LIMITED by Challenger Gold Limited

Challenger Gold Ltd

COLLINS FOODS LTD NWMKT by Collins Foods Ltd Newmarket Qld

Collins Foods Ltd

BICO Group AB

COLLECTIVE METALS INC by COLLECTIVE METALS INC.

Collective Metals Inc

CELLNEX TELECOM UNSP/ADR by Cellnex Telecom SA

Cellnex Telecom SA

Cellectis S.A. - American Depositary Shares

Cellectis SA

CALLINEX MINES INC by Callinex Mines Inc.

Callinex Mines Inc

Cornerstone Strategic Investment Fund, Inc. Common Shares

Cornerstone Strategic Value Fund Inc

Climb Global Solutions, Inc. - Common Stock

Climb Global Solutions Inc

CALIMA ENERGY LTD NEW by Calima Energy Ltd.

Calima Energy Ltd

CALGRO M3 HOLDINGS LTD by Calgro M3 Holdings Ltd.

Calgro M3 Holdings Ltd

Climeon AB

CANADIAN PREM SAND by Canadian Prem Sand Inc.

Canadian Premium Sand Inc

Calumet Inc

Clean Energy Fuels Corp

CALIAN GROUP LTD ORD by Calian Group Ltd.

Calian Group Ltd

Clene Inc

NYLI Cleaner Transport ETF

CLEAN VISION CORPORATION by Clean Vision Corporation

Clean Vision Corp

CELLNEX TELECOM SA ORD by Cellnex Telecom SA

Callisto - United States Dollar

iShares AAA CLO Active ETF

CloakCoin

VanEck ETF Trust VanEck AA-BB CLO ETF

Stifel analyst Mark Astrachan maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Hold and lowers the price target from $101 to $95.

News

Price Target

Analyst Ratings

Stifel Maintains Hold on Colgate-Palmolive, Lowers Price Target to $95

Barclays analyst Lauren Lieberman maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Equal-Weight and lowers the price target from $96 to $83.

Barclays Maintains Equal-Weight on Colgate-Palmolive, Lowers Price Target to $83

UBS analyst Peter Grom maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Buy and lowers the price target from $112 to $104.

UBS Maintains Buy on Colgate-Palmolive, Lowers Price Target to $104

JP Morgan analyst Andrea Teixeira maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $109 to $103.

JP Morgan Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $103

Colgate-Palmolive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) short percent of float has risen 4.59% since its last report. The company recently reported that it has 9.29 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Colgate-Palmolive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736538310_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Colgate-Palmolive has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Colgate-Palmolive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Colgate-Palmolive's peer group average for short interest as a percentage of float is 6.28%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Colgate-Palmolive's Recent Short Interest

TD Cowen analyst Robert Moskow maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Buy and lowers the price target from $110 to $100.

TD Cowen Maintains Buy on Colgate-Palmolive, Lowers Price Target to $100

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Colgate-Palmolive and provided 12-month price targets. The average target is $102.0, accompanied by a high estimate of $114.00 and a low estimate of $83.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.27%. 
<img src="https://www.benzinga.com/files/images/story/2025/1736272811_0_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Colgate-Palmolive by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$92.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$113.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Colgate-Palmolive. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Colgate-Palmolive compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Colgate-Palmolive's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Colgate-Palmolive's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Colgate-Palmolive analyst ratings.</a>
<h2>Unveiling the Story Behind Colgate-Palmolive</h2>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Financial Insights: Colgate-Palmolive</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Colgate-Palmolive's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.4% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Colgate-Palmolive's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.64% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Colgate-Palmolive's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 264.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Colgate-Palmolive's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 4.43%, the company showcases efficient use of assets and strong financial health.
Debt Management: Colgate-Palmolive's debt-to-equity ratio stands notably higher than the industry average, reaching 19.39. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Colgate-Palmolive In The Eyes Of 6 Experts

Wells Fargo analyst Chris Carey maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Underweight and lowers the price target from $92 to $83.

Wells Fargo Maintains Underweight on Colgate-Palmolive, Lowers Price Target to $83

WIIM

Colgate-Palmolive shares are trading lower after Piper Sandler maintained an Overweight rating on the stock but lowered its price target from $121 to $112.

Piper Sandler analyst Korinne Wolfmeyer maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Overweight and lowers the price target from $121 to $112.

Piper Sandler Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $112

<a href="https://www.bloomberg.com/news/articles/2024-11-19/tom-s-of-maine-toothpaste-has-a-bacteria-problem-fda-finds" title="https://www.bloomberg.com/news/articles/2024-11-19/tom-s-of-maine-toothpaste-has-a-bacteria-problem-fda-finds">https://www.bloomberg.com/news/articles/2024-11-19/tom-s-of-maine-toothpaste-has-a-bacteria-problem-fda-finds</a>
US inspectors found Tom's of Maine toothpaste was made with water containing multiple strains of dangerous bacteria and sold to consumers anyway, according to a warning letter posted Tuesday.

'Tom's of Maine Toothpaste Has a Bacteria Problem, FDA Finds' - Bloomberg News

Cresco Labs Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#CSE">CL</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTCQX">CRLBF</a>) (FSE: 6CQ) a company behind Sunnyside dispensaries, released its financial and operating results on Friday for the third quarter ended September 30, 2024.
"So far this year, we've generated $103 million in operating cashflow, enabling us to reinvest in our core, and to explore new markets and growth verticals, all while improving our balance sheet and paying down debt," CEO and co-founderCharlie Bachtell said.
<h3 class="wp-block-heading">Q3 2024 Financial Highlights</h3>
<ul>
<li>Third quarter revenue of $179.8 million representing a 3.2% sequential drop and a 5.7% decrease from the same quarter of last year.</li>
<li>Gross profit of $93.4 million, compared to a $93.6 million gross profit in the corresponding period of last year, and $94.8 million gross profit in the previous period.</li>
<li>Adjusted gross profit, a non-GAAP measure, was $95.3 million, and an adjusted gross margin of 53% of revenue, a 250 bps improvement year-over-year.</li>
<li>Selling, general and administrative expenses of $57 million. Reduced adjusted SG&amp;A by 6% year-over-year to $53 million, or 30% of revenue.</li>
<li>Net loss was $7.7 million, down 93% year-over-year and 84% quarter-over-quarter.</li>
<li>Third quarter Adjusted EBITDA came in positive at $51 million, up 5% year-over-year; Adjusted EBITDA margin of 29%, a 280 bps improvement year-over-year.</li>
<li>Record third-quarter operating cash flow of $49 million and free cash flow of $43 million.</li>
<li>Adjusted EBITDA, a non-GAAP measure, came in positive at $51.3 million, down from an adjusted EBITDA gain of $49 million in the prior year's period and $53.9 million in the prior quarter.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40259646/cannabis-co-cresco-labs-q2-gross-profit-increases-over-9-yoy-reports-nearly-7-drop-in-revenue">Cannabis Co. Cresco Lab&#8217;s Q2 Gross Profit Increases Over 9% YoY, Reports Nearly 7% Drop In Revenue</a>
As of Sept. 30, 2024, assets were $312 million, including cash, cash equivalents and restricted cash of $157 million.
The company had senior secured term loan debt, net of discount and issuance costs, of $390 million and a mortgage loan, net of discount and issuance costs of $18 million.
On Oct. 25, 2024, the company repurchased a $40 million principal amount of its senior loan and paid $0.3 million of accrued Interest.
Cresco Labs made its debut in Chicago in 2013 when Illinois passed the Compassionate Use of Medical Cannabis Act. &#8220;The company's goal and that of its management team has been to help normalize and professionalize this industry,&#8221; Bachtell told the crowd gathered at the <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a> <a href="https://www.benzinga.com/markets/cannabis/24/10/41258536/exclusive-cannabis-companies-must-get-more-juice-from-the-same-squeeze-says-cresco-labs-ceo-as-c" target="_blank" rel="noreferrer noopener">in Chicago in early October.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40779975/is-cresco-labs-an-overlooked-cannabis-stock-market-potential-in-ohio-florida-pennsy">Is Cresco Labs An Overlooked Cannabis Stock? Market Potential In Ohio, Florida &amp; Pennsylvania Promise Opportunity</a></li>
</ul>

Cannabis

Earnings

CRLBF

CSE:CL

Cannabis Co. Cresco Labs' 93% YoY Improvement In Net Loss, $49M Operating Cash Flow In Q3

On November 7, it was revealed in an SEC filing that STANLEY SUTULA III, Chief Financial Officer at Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000021665/000122520824009716//Archives/edgar/data/21665/000122520824009716/0001225208-24-009716-index.htm">U.S. Securities and Exchange Commission</a> on Thursday revealed that III, Chief Financial Officer at Colgate-Palmolive in the Consumer Staples sector, exercised stock options for 45,410 shares of CL stock. The exercise price of the options was $77.04 per share.
The Friday morning update indicates Colgate-Palmolive shares up by 0.94%, currently priced at $95.15. At this value, III's 45,410 shares are worth $822,375.
<h3>Delving into Colgate-Palmolive's Background</h3>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Understanding the Numbers: Colgate-Palmolive's Finances</h3>
Positive Revenue Trend: Examining Colgate-Palmolive's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.4% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 61.08%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Colgate-Palmolive's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.9.
</li>
</ul>
Debt Management: Colgate-Palmolive's debt-to-equity ratio surpasses industry norms, standing at 19.39. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 26.08 is lower than the industry average, implying a discounted valuation for Colgate-Palmolive's stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 3.72 is above industry norms, reflecting an elevated valuation for Colgate-Palmolive's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 17.77, Colgate-Palmolive demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000021665">Check Out The Full List Of Colgate-Palmolive's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Unloading: STANLEY SUTULA III Sells Options, Realizes $822K

In a new SEC filing on November 5, it was revealed that III, Chief Financial Officer at Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), executed a significant exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000021665/000122520824009620//Archives/edgar/data/21665/000122520824009620/0001225208-24-009620-index.htm">U.S. Securities and Exchange Commission</a>, III, Chief Financial Officer at Colgate-Palmolive, exercised stock options for 50,000 shares of CL. The transaction value amounted to $905,500.
The Wednesday morning update indicates Colgate-Palmolive shares up by 0.94%, currently priced at $95.15. At this value, III's 50,000 shares are worth $905,500.
<h3>Unveiling the Story Behind Colgate-Palmolive</h3>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Colgate-Palmolive's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Colgate-Palmolive showcased positive performance, achieving a revenue growth rate of 2.4% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 61.08%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.9, Colgate-Palmolive showcases strong earnings per share.
</li>
</ul>
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 19.39, caution is advised due to increased financial risk.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 27.09, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.87, Colgate-Palmolive's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): A high EV/EBITDA ratio of 18.39 positions the company as being more valued compared to industry benchmarks.
</li>
</ul>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000021665">Check Out The Full List Of Colgate-Palmolive's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

At Colgate-Palmolive, STANLEY SUTULA III Chooses To Exercise Options, Resulting In $905K

Wells Fargo analyst Chris Carey maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Underweight and lowers the price target from $100 to $92.

Wells Fargo Maintains Underweight on Colgate-Palmolive, Lowers Price Target to $92

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Meta Marshall downgraded the rating for Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from Overweight to Equal-Weight and maintained the price target of $63. Ciena shares closed at $64.12 on Friday. <a href="https://www.benzinga.com/quote/ciwn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Joseph Moore downgraded GLOBALFOUNDRIES Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) from Overweight to Equal-Weight and slashed the price target from $53 to $43. GLOBALFOUNDRIES shares closed at $40.40 on Friday. <a href="https://www.benzinga.com/quote/GFFS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Janney Montgomery Scott analyst Feddie Strickland downgraded the rating for WSFS Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSFS#NASDAQ">WSFS</a>) from Buy to Neutral. WSFS Financial shares closed at $49.10 on Friday. <a href="https://www.benzinga.com/quote/WSFS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson downgraded TriNet Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) from Buy to Hold and maintained the price target of $140. Trinet shares closed at $80.31 on Friday. <a href="https://www.benzinga.com/quote/TNET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Mark Astrachan downgraded the rating for Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) from Buy to Hold and lowered the price target from $105 to $101. Colgate-Palmolive shares closed at $95.61 on Friday. <a href="https://www.benzinga.com/quote/CL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28092552/image-276-1024x538.png" alt="" class="wp-image-617112" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28092552/image-276-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28092552/image-276-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28092552/image-276-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/28092552/image-276.png 1221w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41573022/how-to-earn-500-a-month-from-ford-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Ford Stock Ahead Of Q3 Earnings</a></li>
</ul>

Downgrades

CIEN

TNET

WSFS

This Colgate-Palmolive Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Ratings for Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $111.0, a high estimate of $122.00, and a low estimate of $100.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.72%. 
<img src="https://www.benzinga.com/files/images/story/2024/1730120417_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Colgate-Palmolive. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Moskow</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Astrachan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$101.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$114.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Korinne Wolfmeyer</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$121.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Underweight</td>
<td>$100.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Powers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$109.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$119.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Colgate-Palmolive. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Colgate-Palmolive compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Colgate-Palmolive's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Colgate-Palmolive's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Colgate-Palmolive analyst ratings.</a>
<h2>About Colgate-Palmolive</h2>
Since its founding in 1806, Colgate-Palmolive has grown to become a leading player in the household and personal care arena. In addition to its namesake oral care line (which accounts for more than 40% of its total sales), the firm manufactures shampoos, shower gels, deodorants, and homecare products that are sold in over 200 countries. International sales account for about 70% of its total business, including approximately 45% from emerging regions. It also owns specialty pet food maker Hill's (around one fifth of sales), which primarily sells its products through veterinarians and specialty pet retailers.
<h3>Key Indicators: Colgate-Palmolive's Financial Health</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Colgate-Palmolive displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 4.89%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Staples sector.
Net Margin: Colgate-Palmolive's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.45%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Colgate-Palmolive's ROE excels beyond industry benchmarks, reaching 414.16%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Colgate-Palmolive's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.42% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Colgate-Palmolive's debt-to-equity ratio is notably higher than the industry average. With a ratio of 70.54, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Colgate-Palmolive

TD Cowen analyst Robert Moskow maintains Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) with a Buy and lowers the price target from $115 to $110.

TD Cowen Maintains Buy on Colgate-Palmolive, Lowers Price Target to $110

Stifel analyst Mark Astrachan downgrades Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) from Buy to Hold and lowers the price target from $105 to $101.

Stifel Downgrades Colgate-Palmolive to Hold, Lowers Price Target to $101

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Friday.
U.S. stocks settled mixed on Friday, with the Nasdaq Composite surging to an all-time high during the session.
Tech stocks provided a boost to the market ahead of their upcoming quarterly earnings. Shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAZN#NASDAQ">AMAZN</a>) settled higher on Friday.
Both the Dow Jones and S&amp;P 500 ended a six-week winning streak, falling around 1% and 2.7%, respectively. The Nasdaq recorded gains for the seventh straight week, gaining nearly 0.2% last week.
Shares of HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) fell around 9% on Friday after the company reported weaker-than-expected third-quarter financial results. Colgate-Palmolive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) shares fell around 4% after the company reported third-quarter earnings.
On the economic data front, the University of Michigan consumer sentiment for the U.S. rose to 70.5 in October compared to a preliminary reading of 68.9. U.S. durable goods orders fell by 0.8% to $284.8 billion in September compared to a revised 0.8% fall in August.
Most sectors on the S&amp;P 500 closed on a negative note, with financials, real estate, and utilities stocks recording the biggest losses on Friday. However, information technology and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 260 points to 42,114.40 on Friday. The S&amp;P 500 fell 0.03% to 5,808.12, while the Nasdaq Composite climbed 0.56% at 18,518.61 during Friday's session.
Investors are awaiting earnings results from ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>), Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>), and Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 58.9, the index remained in the &#8220;Greed&#8221; zone on Friday, versus a prior reading of 61.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41545103/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Pre-Market Outlook

Markets

AMAZN

NVDA

Nasdaq Surges To Fresh Highs As Nvidia, Meta And Amazon Register Gains: Fear Index Remains In 'Greed' Zone

Dividend Roundup: Citigroup, Procter & Gamble, Caterpillar, CVS Health, and more

General optimism for the U.S. economy has been disrupted by uncertainty surrounding policy changes, geopolitical tensions, and border crises. Amid this volatility, investing in sound consumer staple stocks Colgate-Palmolive (CL), Chewy (CHWY), and Kimberly-Clark (KMB) could offer investors a reliable path to steady returns. Read more… With President-elect Donald Trump's second term beginning in less than two weeks, the U.S. economy has yet to fend off market uncertainties positively. Geopolitical crises, incoming policy changes, and an existing border crisis have turned up the volatility knob, leading to an uncertain market.
Amid this, consumer staples remain a stable investment option, acting as a buffer against these uncertainties. Thus, investors could scoop up shares of fundamentally stable consumer staple stocks Colgate-Palmolive Company (<a href="https://stocknews.com/stock/CL/">CL</a>), Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>), and Kimberly-Clark Corporation (<a href="https://stocknews.com/stock/KMB/">KMB</a>) to look for steady returns in these uncertain times.
With his proposed <a href="https://abcnews.go.com/Business/trumps-proposed-tariffs-raise-prices-products-experts/story?id=115893557">60% tariffs on Chinese goods</a> and a pledged 25% tariff on Canadian imports within his initial days in office, Trump's statements on trade policies have not been perceived as the most welcoming message to world leaders. Corporations, no matter how big or small, are expected to take a hit due to these tariff changes.
On the other hand, Trump's stance on <a href="https://www.brookings.edu/articles/how-is-trumps-reelection-likely-to-affect-us-foreign-policy/">the U.S.-Mexico border crisis</a> threatens to deepen challenges between the two nations. This means a threat to both the Mexican and American economies as interchanged goods and services between these two nations are to face significant red tape going forward.
Additionally, Trump's vows to end the Ukraine-Russia war, the ongoing altercation in the Middle East, as well as his ‘joking' statement to include <a href="https://www.forbes.com/sites/mollybohannon/2025/01/06/trump-says-canada-should-merge-with-us-trolling-trudeau-as-he-steps-down/">Canada as the 51st U.S. State</a> have all contributed to the mix of political and global uncertainty. Furthermore, hints of wanting the Panama Canal and Greenland under American control or ownership have also been observed.
Amid this concerning politically uncertain times, consumer staples remain a stable investment option. These products maintain the principle of <a href="https://www.investopedia.com/terms/e/inelastic.asp">inelastic demand</a>, holding their needs and demand even if costs climb.
So now, let us dive deep into the fundamentals of three <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> stocks, starting with #3.
Stock #3: Colgate-Palmolive Company (<a href="https://stocknews.com/stock/CL/">CL</a>)
CL manufactures and sells consumer products. The company has two segments: Oral, Personal and Home Care; and Pet Nutrition. It sells its products under various brands such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, and more.
CL's trailing-12-month <a href="https://www.investopedia.com/terms/g/gross_profit_margin.asp">gross profit margin</a> of 60.42% is 66.4% higher than the industry average of 36.32%. Its trailing-12-month levered FCF margin of 14.82% is 161.6% higher than the sector average of 5.66%. Furthermore, the stock's trailing-12-month net income margin of 14.26% is 232.3% higher than the 4.29% industry average.
For the fiscal 2024 third quarter that ended September 30, CL's net sales increased 2.4% year-over-year to $5.03 billion. Its non-GAAP operating profit increased 4.8% year-over-year to $1.08 billion.
Additionally, non-GAAP net income attributable to CL and non-GAAP EPS grew 5.6% and 5.8% from the prior year's quarter to $750 million and $0.91, respectively.
Analysts expect CL's revenue and EPS for the fiscal 2024 fourth quarter (ended December 2024) to increase 1.7% and 3.2% year-over-year to $5.04 billion and $0.90, respectively. Additionally, the company topped the consensus revenue and EPS estimates in all four trailing quarters, which is noteworthy.
CL's shares have surged 9.3% over the past year to close the last trading session at $87.39.
CL's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its fundamentals. The stock has an A grade for Quality and a B for Stability. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
Within the <a href="https://stocknews.com/category/consumer-goods/">Consumer Goods</a> industry, CL is ranked #18 out of 54 stocks. In addition to the POWR Rating highlighted above, you can check CL's ratings for Growth, Momentum, Sentiment, and Value <a href="https://stocknews.com/stock/CL/">here</a>.
Stock #2: Chewy, Inc. (<a href="https://stocknews.com/stock/CHWY/">CHWY</a>)
CHWY is a dedicated e-commerce platform specializing in pet care. It provides a comprehensive range of products and services, including pet food, treats, supplies, medications, and services for a variety of pets, dogs, cats, fish, birds, small animals, horses, and reptiles, accessible through its retail websites and mobile apps.
CHWY's trailing-12-month ROCE of 130.34% is significantly higher than the industry average of 10.88%. Its trailing-12-month ROTC of 7.31% is 17.4% higher than the sector average of 6.22%. Likewise, the stock's trailing-12-month asset turnover ratio of 3.88x is 295% higher than the industry average of 0.98x.
For the fiscal 2025 third quarter that ended October 27, 2024, CHWY's net sales increased 4.8% year-over-year to $2.88 billion. Its income from operations amounted to $25.63 million, compared to a loss from operations of $9.72 million the previous year's quarter.
Moreover, adjusted net income and adjusted EPS attributable to common Class A and Class B stockholders grew 33.8% and 33.3% from the year-ago value to $84.92 million and $0.20, respectively.
Street expects CHWY's revenue and EPS for the fiscal 2025 fourth (quarter ending January 2025) to increase 12.9% and 10.4% year-over-year to $3.19 billion and $0.20, respectively. Moreover, the company topped the consensus revenue estimates in all four trailing quarters, which is noteworthy.
Shares of CHWY have surged 43.2% over the past six months and 75.1% over the past year, closing the last trading session at $35.77.
CHWY's sound fundamentals are mirrored in its POWR Ratings. The stock has an overall rating of B, translating to a Buy in our proprietary rating system.
CHWY has a B grade for Quality. Within the Consumer Goods industry, it is ranked #13 out of 54 stocks.
To access CHWY's Growth, Stability, Value, Momentum, and Sentiment ratings, <a href="https://stocknews.com/stock/CHWY/">click here</a>.
Stock #1: Kimberly-Clark Corporation (<a href="https://stocknews.com/stock/KMB/">KMB</a>)
KMB manufactures and markets personal care and consumer tissue products. The company has three segments: Personal Care; Consumer Tissue; and K-C Professional. It offers products under brands like Huggies, Pull-Ups, Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, and more.
On December 26, 2024, KMB announced <a href="https://investor.kimberly-clark.com/2024-12-26-Indias-Thriving-Tech-Hub-Fuels-Kimberly-Clarks-Digital-Transformation">significant digital transformation</a> through its  Global Digital Technology Center (GDTC) in Bengaluru, India. Established with an initial investment of $2.5 million, this GDTC focuses on key areas and digital capabilities such as Data and Analytics, Artificial Intelligence (AI) including Generative AI, Machine Learning (ML), Cloud Transformation, and more.
The Bengaluru GDTC is set to continue its expansion, focusing on advancing AI/ML capabilities and developing innovative digital solutions to boost operational efficiency and customer engagement, contributing to India's broader tech and innovation ecosystem and enhancing the company's global presence.
KMB's trailing-12-month levered FCF margin of 12.41% is 119.1% higher than the industry average of 5.66%. Its trailing-12-month EBITDA margin of 19.39% is 52% higher than the 12.76% industry average. Additionally, the stock's trailing-12-month net income margin of 12.97% is 202.2% higher than the sector average of 4.29%.
For the fiscal third quarter that ended September 30, 2024, KMB's net sales came in at $4.95 billion. Its operating profit increased 49.1% year-over-year to $1.15 billion.
Additionally, adjusted net income attributable to KMB and adjusted EPS rose 4.6% and 5.2% from the prior year's quarter to $617 million and $1.83, respectively.
The consensus revenue estimate for the fiscal year ending December 2025 amounts to $20 billion. Its EPS for the same period is expected to rise 4.2% year-over-year to $7.63. Furthermore, the company surpassed the consensus EPS estimates in three of four trailing quarters.
Shares of KMB have surged marginally over the past nine months and 4.1% over the past year to close the last trading session at $127.30.
KMB's POWR Ratings reflect its robust prospects. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
KMB has a B grade for Quality, Value, and Sentiment. It is ranked #5 out of 54 stocks in the Consumer Goods industry.
<a href="https://stocknews.com/stock/KMB/">Click here</a> to access KMB's ratings for Stability, Momentum, and Growth.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
CL shares were unchanged in premarket trading Wednesday. Year-to-date, CL has declined -3.87%, versus a 0.44% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aritra_Gangopadhyay</h2> <img src='https:/wp-content/uploads/2025/01/Aritra_Gangopadhyay.png' style="float:left; padding:5px;width:125px;">Aritra is a financial journalist dedicated to breaking down complex financial topics into simple, actionable insights. Holding a Master's degree in Economics, he uses his analytical expertise to help investors uncover unique opportunities for long-term success.<a href="https://stocknews.com/authors/?author=aritra-gangopadhyay">More...</a>The post <a href=https://stocknews.com/news/cl-kmb-chwy-3-consumer-staples-stocks-for-steady-returns-in-uncertain-times/>3 Consumer Staples Stocks for Steady Returns in Uncertain Times</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Comments

Colgate-Palmolive

Colgate-Palmolive (CL) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL